BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/29/2026 7:26:46 AM | Browse: 2 | Download: 15
 |
Received |
|
2026-01-06 09:18 |
|
Peer-Review Started |
|
2026-01-06 09:19 |
|
First Decision by Editorial Office Director |
|
2026-01-19 08:52 |
|
Return for Revision |
|
2026-01-19 08:52 |
|
Revised |
|
2026-01-29 14:59 |
|
Publication Fee Transferred |
|
2026-02-02 00:49 |
|
Second Decision by Editor |
|
2026-03-17 03:07 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-17 10:07 |
|
Articles in Press |
|
2026-03-17 10:07 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-15 01:47 |
|
Publish the Manuscript Online |
|
2026-05-29 07:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Study |
| Article Title |
Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hui-Bin Ning, Hui-Ming Jin, Zhen Peng, Kuan Li and Jia Shang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jia Shang, Chief Physician, Department of Infectious Diseases, Henan Provincial People's Hospital, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450000, Henan Province, China. shangjia666@126.com |
| Key Words |
Chronic hepatitis B; Entecavir; Tenofovir alafenamide fumarate; Bone safety; Renal safety |
| Core Tip |
Nucleoside/nucleotide analogs are currently the core drugs for the antiviral treatment of chronic hepatitis B (CHB). Among them, entecavir and tenofovir alafenamide fumarate (TAF) are recommended as first-line treatment regimens in domestic and international guidelines due to their potent antiviral activity and low resistance rates. However, direct comparative data between TAF and entecavir remain limited, particularly in long-term follow-up studies of Chinese CHB populations. The long-term differences in bone and renal safety between TAF and entecavir warrant further investigation. Therefore, this study aims to provide critical insights for optimizing individualized treatment strategies for CHB by comparing the clinical efficacy and safety profiles of entecavir and TAF. |
| Publish Date |
2026-05-29 07:26 |
| Citation |
Ning HB, Jin HM, Peng Z, Li K, Shang J. Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B. World J Gastroenterol 2026; 32(22): 117500 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i22/117500.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i22.117500 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
